CVS Health Corporation (NYSE:CVS) Analyst Ratings and Price Targets
CVS Health Corporation (NYSE:CVS) is a leading entity in the healthcare sector, recognized for its expansive network of pharmacies and diverse healthcare services. With operations spread across the United States, CVS plays a pivotal role in providing vital services ranging from retail pharmacy to health insurance. The company faces intense competition from other prominent healthcare providers such as Walgreens and Rite Aid, which continually shapes its market strategies and performance.
Recent Analyst Ratings and Price Targets
- Kevin Caliendo from UBS has recently set a price target of $97 for CVS, which implies a potential increase of about 24% from its current trading price of $78.24.
- Wolfe Research has upgraded CVS’s price target from $85 to $100, reflecting a positive shift in market sentiment towards the stock.
- In contrast, Zacks Research has downgraded CVS from a “strong-buy” to a “hold” rating, indicating some caution among analysts despite the prevailing optimistic outlook.
Market Sentiment and Stock Performance
As of December 10, 2025, CVS’s stock opened at $79.14 following Wolfe Research’s upgrade, suggesting an encouraging market response to the revised price target. The upgrades from various analysts, including a notable increase from Leerink Partners, which raised its price objective from $86 to $95, showcase a strong belief in CVS’s future potential. Evercore ISI also increased their target from $85 to $95, maintaining an “outperform” rating, which further supports the bullish sentiment surrounding CVS.
Despite the positive outlook from several quarters, the recent downgrade by Zacks Research serves as a reminder of the inherent volatility and risk associated with the stock market. Zacks’s shift from a “strong-buy” to a “hold” indicates that while CVS shows promise, investors should exercise caution and monitor market conditions closely.
Current Stock Data and Market Capitalization
As of the latest trading session, CVS’s stock price has experienced a modest increase of 2.23%, with a trading volume of 12.58 million shares on the NYSE. The company boasts a market capitalization of approximately $99.32 billion, illustrating its significant footprint in the healthcare industry. The stock has shown fluctuations, with a daily trading range between a low of $78.22 and a high of $80.50. Over the past 52 weeks, CVS’s stock has seen a range from $43.56 to $85.15, highlighting the stock’s dynamic nature influenced by varying market trends and analyst ratings.
Conclusion
In summary, CVS Health Corporation continues to be a key player in the healthcare sector, with analysts expressing a mix of optimism and caution regarding its future performance. The recent price target upgrades signal a growing confidence in the company’s ability to navigate the competitive landscape, while the downgrade from Zacks serves as a critical reminder for investors to remain vigilant. As CVS continues to adapt to the changing healthcare environment, its stock performance will be closely watched by investors seeking opportunities in the healthcare market.
